These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

117 related items for PubMed ID: 27317648

  • 1. F25P preproinsulin abrogates the secretion of pro-growth factors from EGFRvIII cells and suppresses tumor growth in an EGFRvIII/wt heterogenic model.
    Wei JW, Cui JQ, Zhou X, Fang C, Tan YL, Chen LY, Yang C, Liu M, Kang CS.
    Cancer Lett; 2016 Sep 28; 380(1):1-9. PubMed ID: 27317648
    [Abstract] [Full Text] [Related]

  • 2. Sym004-induced EGFR elimination is associated with profound anti-tumor activity in EGFRvIII patient-derived glioblastoma models.
    Keir ST, Chandramohan V, Hemphill CD, Grandal MM, Melander MC, Pedersen MW, Horak ID, Kragh M, Desjardins A, Friedman HS, Bigner DD.
    J Neurooncol; 2018 Jul 28; 138(3):489-498. PubMed ID: 29564747
    [Abstract] [Full Text] [Related]

  • 3. EGFRvIII/integrin β3 interaction in hypoxic and vitronectinenriching microenvironment promote GBM progression and metastasis.
    Liu Z, Han L, Dong Y, Tan Y, Li Y, Zhao M, Xie H, Ju H, Wang H, Zhao Y, Zheng Q, Wang Q, Su J, Fang C, Fu S, Jiang T, Liu J, Li X, Kang C, Ren H.
    Oncotarget; 2016 Jan 26; 7(4):4680-94. PubMed ID: 26717039
    [Abstract] [Full Text] [Related]

  • 4. EGFRvIII mutations can emerge as late and heterogenous events in glioblastoma development and promote angiogenesis through Src activation.
    Eskilsson E, Rosland GV, Talasila KM, Knappskog S, Keunen O, Sottoriva A, Foerster S, Solecki G, Taxt T, Jirik R, Fritah S, Harter PN, Välk K, Al Hossain J, Joseph JV, Jahedi R, Saed HS, Piccirillo SG, Spiteri I, Leiss L, Euskirchen P, Graziani G, Daubon T, Lund-Johansen M, Enger PØ, Winkler F, Ritter CA, Niclou SP, Watts C, Bjerkvig R, Miletic H.
    Neuro Oncol; 2016 Dec 26; 18(12):1644-1655. PubMed ID: 27286795
    [Abstract] [Full Text] [Related]

  • 5. Aptamer targeting EGFRvIII mutant hampers its constitutive autophosphorylation and affects migration, invasion and proliferation of glioblastoma cells.
    Camorani S, Crescenzi E, Colecchia D, Carpentieri A, Amoresano A, Fedele M, Chiariello M, Cerchia L.
    Oncotarget; 2015 Nov 10; 6(35):37570-87. PubMed ID: 26461476
    [Abstract] [Full Text] [Related]

  • 6. The EGFRvIII variant in glioblastoma multiforme.
    Gan HK, Kaye AH, Luwor RB.
    J Clin Neurosci; 2009 Jun 10; 16(6):748-54. PubMed ID: 19324552
    [Abstract] [Full Text] [Related]

  • 7. Maintenance of EGFR and EGFRvIII expressions in an in vivo and in vitro model of human glioblastoma multiforme.
    Stockhausen MT, Broholm H, Villingshøj M, Kirchhoff M, Gerdes T, Kristoffersen K, Kosteljanetz M, Spang-Thomsen M, Poulsen HS.
    Exp Cell Res; 2011 Jul 01; 317(11):1513-26. PubMed ID: 21514294
    [Abstract] [Full Text] [Related]

  • 8. Signal Peptide Peptidase, Encoded by HM13, Contributes to Tumor Progression by Affecting EGFRvIII Secretion Profiles in Glioblastoma.
    Wei JW, Cai JQ, Fang C, Tan YL, Huang K, Yang C, Chen Q, Jiang CL, Kang CS.
    CNS Neurosci Ther; 2017 Mar 01; 23(3):257-265. PubMed ID: 28198167
    [Abstract] [Full Text] [Related]

  • 9. Selective coexpression of VEGF receptor 2 in EGFRvIII-positive glioblastoma cells prevents cellular senescence and contributes to their aggressive nature.
    Jones KA, Gilder AS, Lam MS, Du N, Banki MA, Merati A, Pizzo DP, VandenBerg SR, Gonias SL.
    Neuro Oncol; 2016 May 01; 18(5):667-78. PubMed ID: 26420897
    [Abstract] [Full Text] [Related]

  • 10. Construction of an immunotoxin, D2C7-(scdsFv)-PE38KDEL, targeting EGFRwt and EGFRvIII for brain tumor therapy.
    Chandramohan V, Bao X, Keir ST, Pegram CN, Szafranski SE, Piao H, Wikstrand CJ, McLendon RE, Kuan CT, Pastan IH, Bigner DD.
    Clin Cancer Res; 2013 Sep 01; 19(17):4717-27. PubMed ID: 23857604
    [Abstract] [Full Text] [Related]

  • 11. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.
    Luchman HA, Stechishin OD, Nguyen SA, Lun XQ, Cairncross JG, Weiss S.
    Clin Cancer Res; 2014 Nov 15; 20(22):5756-67. PubMed ID: 25316808
    [Abstract] [Full Text] [Related]

  • 12. Knockdown of long non-coding RNA XIST exerts tumor-suppressive functions in human glioblastoma stem cells by up-regulating miR-152.
    Yao Y, Ma J, Xue Y, Wang P, Li Z, Liu J, Chen L, Xi Z, Teng H, Wang Z, Li Z, Liu Y.
    Cancer Lett; 2015 Apr 01; 359(1):75-86. PubMed ID: 25578780
    [Abstract] [Full Text] [Related]

  • 13. An EGFR wild type-EGFRvIII-HB-EGF feed-forward loop regulates the activation of EGFRvIII.
    Li L, Chakraborty S, Yang CR, Hatanpaa KJ, Cipher DJ, Puliyappadamba VT, Rehman A, Jiwani AJ, Mickey B, Madden C, Raisanen J, Burma S, Saha D, Wang Z, Pingle SC, Kesari S, Boothman DA, Habib AA.
    Oncogene; 2014 Aug 14; 33(33):4253-64. PubMed ID: 24077285
    [Abstract] [Full Text] [Related]

  • 14. Differential gene expression analysis reveals generation of an autocrine loop by a mutant epidermal growth factor receptor in glioma cells.
    Ramnarain DB, Park S, Lee DY, Hatanpaa KJ, Scoggin SO, Otu H, Libermann TA, Raisanen JM, Ashfaq R, Wong ET, Wu J, Elliott R, Habib AA.
    Cancer Res; 2006 Jan 15; 66(2):867-74. PubMed ID: 16424019
    [Abstract] [Full Text] [Related]

  • 15. EGFR/EGFRvIII remodels the cytoskeleton via epigenetic silencing of AJAP1 in glioma cells.
    Yang C, Li YS, Wang QX, Huang K, Wei JW, Wang YF, Zhou JH, Yi KK, Zhang KL, Zhou BC, Liu C, Zeng L, Kang CS.
    Cancer Lett; 2017 Sep 10; 403():119-127. PubMed ID: 28634045
    [Abstract] [Full Text] [Related]

  • 16. Human glioblastoma xenografts overexpressing a tumor-specific mutant epidermal growth factor receptor sensitized to cisplatin by the AG1478 tyrosine kinase inhibitor.
    Nagane M, Narita Y, Mishima K, Levitzki A, Burgess AW, Cavenee WK, Huang HJ.
    J Neurosurg; 2001 Sep 10; 95(3):472-9. PubMed ID: 11565870
    [Abstract] [Full Text] [Related]

  • 17. Inhibition of the type III epidermal growth factor receptor variant mutant receptor by dominant-negative EGFR-CD533 enhances malignant glioma cell radiosensitivity.
    Lammering G, Hewit TH, Holmes M, Valerie K, Hawkins W, Lin PS, Mikkelsen RB, Schmidt-Ullrich RK.
    Clin Cancer Res; 2004 Oct 01; 10(19):6732-43. PubMed ID: 15475464
    [Abstract] [Full Text] [Related]

  • 18. GBM heterogeneity as a function of variable epidermal growth factor receptor variant III activity.
    Lindberg OR, McKinney A, Engler JR, Koshkakaryan G, Gong H, Robinson AE, Ewald AJ, Huillard E, David James C, Molinaro AM, Shieh JT, Phillips JJ.
    Oncotarget; 2016 Nov 29; 7(48):79101-79116. PubMed ID: 27738329
    [Abstract] [Full Text] [Related]

  • 19. The role of sphingosine kinase-1 in EGFRvIII-regulated growth and survival of glioblastoma cells.
    Estrada-Bernal A, Lawler SE, Nowicki MO, Ray Chaudhury A, Van Brocklyn JR.
    J Neurooncol; 2011 May 29; 102(3):353-66. PubMed ID: 20938717
    [Abstract] [Full Text] [Related]

  • 20. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme.
    Shinojima N, Tada K, Shiraishi S, Kamiryo T, Kochi M, Nakamura H, Makino K, Saya H, Hirano H, Kuratsu J, Oka K, Ishimaru Y, Ushio Y.
    Cancer Res; 2003 Oct 15; 63(20):6962-70. PubMed ID: 14583498
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.